functional dyspepsia

From Aaushi
Jump to navigation Jump to search

Introduction

At least 3 months of pain or discomfort centered in the upper abdomen, without clinical, endoscopic, or ultrasonographic evidence of known organic disease likely to explain the symptoms.

Etiology

(differential diagnosis)

* 75% of cases are due to GERD &/or IBS

Pathology

* essentially the same disorder as gastroparesis[4]

Clinical manifestations

* essentially the same disorder as gastroparesis[4]

Diagnostic criteria

Laboratory

Management

More general terms

Additional terms

References

  1. 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 17, 18. American College of Physicians, Philadelphia 1998, 2015, 2018
  2. 2.0 2.1 van Zanten SV et al, Esomeprazole 40 mg once a day in patients with functional dyspepsia: The radomized, placebo-controlled 'ENTER' trial. Am J Gastroenterol 2006, 101:2096 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16817845
  3. Lacy BE, Talley NJ, Locke GR 3rd et al Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012 Jul;36(1):3-15. Epub 2012 May 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22591037
  4. 4.0 4.1 4.2 Pasricha PJ et al. Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathologic features. Gastroenterology 2021 May; 160:2006. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33548234 https://www.gastrojournal.org/article/S0016-5085(21)00337-1/fulltext
    Tack J et al. Gastroparesis: A dead-end street after all? Gastroenterology 2021 May; 160:1931. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33621562 https://www.gastrojournal.org/article/S0016-5085(21)00432-7/fulltext
  5. Hamza Z Probiotics Show Promise for Symptoms of Functional GI Disorders. Small pilot study suggested clinical benefit, acceptable safety profile. https://www.medpagetoday.com/gastroenterology/generalgastroenterology/93951
    Wauters L, Slaets H, De Paepe K et al Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021; Aug 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34358486 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00226-0/fulltext
    Burns GL, Hoedt EC, Keely S Spore-forming probiotics for functional dyspepsia. Lancet Gastroenterol Hepatol 2021; Aug 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34358485 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00260-0/fulltext